A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies
Authors:
- Matthew S. DavidsMDMatthew S. Davids
- Danielle M. BranderDBDanielle M. Brander
- Yesid Alvarado-ValeroYAYesid Alvarado-Valero
- Catherine S. DiefenbachCDCatherine S. Diefenbach
- Daniel N. EganDEDaniel N. Egan
- Shira N. DinnerSDShira N. Dinner
- Nathalie Javidi-SharifiNJNathalie Javidi-Sharifi
- Monzr M. Al MalkiMMMonzr M. Al Malki
- Kebede H. BegnaKBKebede H. Begna
- Vijaya Raj BhattVBVijaya Raj Bhatt
- Sameem AbedinSASameem Abedin
- Rachel J. CookRCRachel J. Cook
Open Access
- 14 February 2025
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (4) , 820-832
Abstract
The antiapoptotic protein, myeloid cell leukemia-1 (Mcl-1), contributes to the pathophysiology of acute myeloid leukemia (AML) and certain B-cell malignancies. Tumor dependence on Mcl-1 is associated with resistance to venetoclax. Voruciclib, an oral cyclin-dependent kinase (CDK) inhibitor targeting CDK9, indirectly decreases Mcl-1 protein expression and synergizes with venetoclax in preclinical models. This dose escalation study evaluated voruciclib in patients with previously treated hematologic malignancies. Initially, voruciclib was administered daily, continuously, on a 28-day cycle (group 1). After 2 patients with prior allogeneic stem cell transplantation had a dose-limiting toxicity (DLT) of interstitial pneumonitis at 100 mg, voruciclib administration was changed to days 1 to 14 of a 28-day cycle (group 2). Forty patients, 21 with AML and 19 with B-cell malignancies, were enrolled. Patients had a median of 3 prior lines of therapy (range, 1-8). Dose escalation in group 2 was stopped at 200 mg, a dose that achieved plasma concentrations sufficient for target inhibition, without DLTs observed. The most common adverse events were diarrhea (30%), nausea (25%), anemia (22%), fatigue (22%), constipation (17%), dizziness (15%), and dyspnea (15%). In AML, 1 patient achieved a morphologic leukemia-free state, and 2 had stable disease. Voruciclib treatment led to a decrease in MCL1 messenger RNA expression, downregulation of myelocytomatosis (MYC) and NF-κB transcriptional gene sets, and reduced phosphorylation of RNA polymerase 2. Voruciclib on intermittent dosing was well tolerated, with no DLTs, paving the way for evaluation of the combination of voruciclib with venetoclax for patients with previously treated AML. This trial was registered at www.clinicaltrials.gov as #NCT03547115.Keywords
This publication has 53 references indexed in Scilit:
- Akt-Dependent Glucose Metabolism Promotes Mcl-1 Synthesis to Maintain Cell Survival and Resistance to Bcl-2 InhibitionCancer Research, 2011
- Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemiasHaematologica, 2010
- Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximabBlood, 2009
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaBlood, 2006
- Conditional transgenic models define how MYC initiates and maintains tumorigenesisSeminars in Cancer Biology, 2006
- Mammalian cyclin-dependent kinasesTrends in Biochemical Sciences, 2005
- Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2Nature, 1990
- Consequences of widespread deregulation of the c-myc gene in transgenic mice: Multiple neoplasms and normal developmentCell, 1986
- The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic miceNature, 1985